Search - tctmd.com

Displaying 41 - 60 of 168

Sort: Relevancy | Date

News Daily News

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

L.A. McKeown

February 19, 2019

Presentation ISET 2019

5-Year Results from the IN.PACT SFA Randomized Trial

Presenter: Gary Ansel

January 30, 2019

Presentation LINC 2019

Insights from the IN.PACT Global Study: Does Lesion Complexity Affect Results?

Presenter: Peter Faries

January 25, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

L.A. McKeown

December 17, 2018

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

L.A. McKeown

November 13, 2018

Presentation TCT 2018

IN.PACT DCB: Pooled Multistudy Assessment of Drug-Coated Balloon Treatment for Femoropopliteal Peripheral Artery Disease

Presenter: Lindsay S. Machan, Craig M. Walker, Mehdi H. Shishehbor

September 22, 2018

News Daily News

CV Devices in the Fast Lane: FDA’s Approval Often Rests on Early Evidence

Caitlin E. Cox

September 05, 2018

News Industry News

Medtronic Receives FDA Approval for 200mm & 250mm IN.PACT(TM) Admiral(TM) Drug Coated Balloons

June 18, 2018

News Daily News

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

L.A. McKeown

May 08, 2018

News Industry News

Medtronic IN.PACT(TM) Admiral(TM) Drug Coated Balloon Receives FDA Approval to Treat Long SFA Lesions

April 24, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Conference News ISET 2018

MIMICS-2 at 1 Year: 3-D Stent Meets Safety and Effectiveness Goals

Caitlin E. Cox

February 08, 2018

Presentation TCT 2017

Long-Term Data With Standard-Dose DCB Technologies (IN.PACT SFA and the Consequent Trial)

Presenter: William A. Gray, Thomas Zeller, Peter A. Schneider

November 01, 2017

Presentation TCT 2017

TCT 57: Comparison of Particulate Embolization After Femoral Artery Treatment with IN.PACT Admiral, Ranger, and Stellarex Paclitaxel-Coated Balloons in Healthy Swine

Presenter: Sahil A. Parikh, Sho Torii, MD

October 31, 2017

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

L.A. McKeown

September 18, 2017

Presentation VIVA 2017

Results from the IN.PACT SFA Randomized Trial

Presenter: Peter A. Schneider

September 15, 2017

Presentation VIVA 2017

Two-year Results from the IN.PACT Global Study

Presenter: Thomas Zeller

September 14, 2017

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

L.A. McKeown

September 13, 2017

Advertisement

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

5-Year Results from the IN.PACT SFA Randomized Trial

Insights from the IN.PACT Global Study: Does Lesion Complexity Affect Results?

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

IN.PACT DCB: Pooled Multistudy Assessment of Drug-Coated Balloon Treatment for Femoropopliteal Peripheral Artery Disease

CV Devices in the Fast Lane: FDA’s Approval Often Rests on Early Evidence

Medtronic Receives FDA Approval for 200mm & 250mm IN.PACT(TM) Admiral(TM) Drug Coated Balloons

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

Medtronic IN.PACT(TM) Admiral(TM) Drug Coated Balloon Receives FDA Approval to Treat Long SFA Lesions

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

MIMICS-2 at 1 Year: 3-D Stent Meets Safety and Effectiveness Goals

Long-Term Data With Standard-Dose DCB Technologies (IN.PACT SFA and the Consequent Trial)

TCT 57: Comparison of Particulate Embolization After Femoral Artery Treatment with IN.PACT Admiral, Ranger, and Stellarex Paclitaxel-Coated Balloons in Healthy Swine

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

Results from the IN.PACT SFA Randomized Trial

Two-year Results from the IN.PACT Global Study

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content